Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 7% of the time (56 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsfailurefunctionstagemyocardial
  Phrases that lowered it: ecgclinical trial40 yearshistoryfourth
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: prevention (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 6.0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports before start: 8848 (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction NCT03087773 · started 2017 · scored riskier than 33% of active trials completed
• Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack. NCT04564742 · started 2020 · scored riskier than 62% of active trials completed
• SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk NCT03151343 · started 2017 · scored riskier than 72% of active trials completed
• Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF NCT07169981 · started 2023 · scored riskier than 23% of active trials completed
• Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure NCT04049045 · started 2019 · scored riskier than 47% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.